Results 271 to 280 of about 161,005 (352)

Investigation of a Truncated Cardiac Troponin T That Causes Familial Hypertrophic Cardiomyopathy

open access: bronze, 2000
Charles Redwood   +9 more
openalex   +1 more source

Validation and correlation of high-sensitive troponin I and troponin T in the emergency department. [PDF]

open access: yesBMC Cardiovasc Disord
Nseir M   +4 more
europepmc   +1 more source

Distinct microbial and metabolic shifts characterize acute coronary syndrome and recovery

open access: yesiMeta, EarlyView.
This study explores the gut–heart axis in coronary artery disease (CAD) using multi‐omics integration of clinical, microbiome and metabolome data. Across healthy controls, stable CAD (sCAD), acute coronary syndrome (ACS), and recovery, we identify stage‐specific microbial dysbiosis and metabolite alterations that mark the transition from stability to ...
Jing Xu   +37 more
wiley   +1 more source

Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans. [PDF]

open access: yesCirculation
Kristensen JH   +22 more
europepmc   +1 more source

Comparative Evaluation of Centrifugation Speed and Its Impact on Diagnostic Accuracy

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
This study evaluates whether high‐speed centrifugation (5 min at 4000 g) can effectively reduce laboratory turnaround time (TAT) without compromising diagnostic accuracy. Results showed that most analytes remained clinically reliable, hemolysis rates were significantly reduced, and the faster method proved to be a safe and efficient alternative for ...
Mohammed A. Jeraiby   +8 more
wiley   +1 more source

High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT. [PDF]

open access: yesHypertension
Haney D   +15 more
europepmc   +1 more source

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Samira Merali   +7 more
wiley   +1 more source

Predictive value and optimal cut-off level of high-sensitivity troponin T in patients with acute pulmonary embolism. [PDF]

open access: yesKorean J Intern Med
Kim M   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy